BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) “ The Transplant Company™ ” a number one precision drugs firm centered on the invention, growth, and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers ” immediately introduced that, as an inducement materials to coming into into employment with CareDx (NASDAQ:), on September 12, 2024, 14 new staff have been awarded restricted inventory models (RSUs) for an mixture of 44,000 shares of frequent inventory. The RSUs have been granted pursuant to the Firm’s 2019 Inducement Fairness Incentive Plan, which was authorized by the Compensation Committee of the Board of Administrators in August 2019 beneath Nasdaq Itemizing Rule 5635(c)(4).
RSUs for an mixture of 9,000 shares vest over 4 years, with 25% of the RSUs vesting on the primary anniversary of the relevant vesting graduation date, and the stability vesting yearly thereafter in three equal installments, topic to the grantee’s continued service by means of every relevant vesting date. RSUs for an mixture of 14,000 shares vest over 4 years, with 25% of the RSUs vesting on the primary anniversary of the relevant vesting graduation date, and the stability vesting quarterly over three years thereafter, topic to the grantee’s continued service by means of every relevant vesting date. RSUs for an mixture of 18,000 shares vest over three years, with 33.33% of the RSUs vesting on the primary anniversary of the relevant vesting graduation date, and the stability vesting quarterly over two years thereafter, topic to the grantee’s continued service by means of every relevant vesting date. RSUs for two,000 shares vest over two years, with 50% of the RSUs vesting on every of the primary two anniversaries of the relevant vesting graduation date, topic to the grantee’s continued service by means of every relevant vesting date. RSUs for 1,000 shares vest over two years, with 50% of the RSUs vesting on the primary anniversary of the relevant vesting graduation date, and the balancing vesting quarterly over the next 12 months thereafter, topic to the grantee’s continued service every relevant vesting date.
CareDx is offering this data in accordance with Nasdaq Itemizing Rule 5635(c)(4).
About CareDx “ The Transplant Firm
CareDx, Inc., headquartered in Brisbane, California, is a number one precision drugs options firm centered on the invention, growth, and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers. CareDx gives testing companies, merchandise, and digital healthcare options alongside the pre- and post-transplant affected person journey and is the main supplier of genomics-based data for transplant sufferers. For extra data, please go to: www.CareDx.com.
Ahead Wanting Statements
This press launch consists of forward-looking statements associated to CareDx, Inc., together with statements concerning the fairness grants. These forward-looking statements are based mostly upon data that’s at the moment accessible to CareDx and its present expectations, converse solely as of the date hereof, and are topic to dangers and uncertainties that would trigger precise outcomes to vary materially from these projected, together with basic financial and market elements; and different dangers mentioned in CareDx’s filings with the SEC, together with the Annual Report on Type 10-Ok for the fiscal 12 months ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Type 10-Q for the fiscal quarter ended March 31, 2024 filed by CareDx with the SEC on Might 9, 2024 and the Quarterly Report on Type 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and different experiences that CareDx has filed with the SEC. Any of those might trigger CareDx’s precise outcomes, efficiency, or achievements to vary materially and adversely from these anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, besides as required by regulation, or enterprise to replace or revise any such forward-looking statements.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20240913883690/en/
CareDx, Inc.
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investor@caredx.com
Supply: CareDx, Inc.
